Your browser doesn't support javascript.
loading
Performance of the shared decision-making process scale for use in evaluation of hereditary cancer genetic testing decisions.
Gore Moses, Rachel; Nieters, Amanda; Valentine, K D; Wooters, Mackenzie; Wynn, Julia; Wardyn, Amy; Amendola, Laura; Sepucha, Karen R; Shannon, Kristen M.
Afiliação
  • Gore Moses R; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Nieters A; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, Massachusetts, USA.
  • Valentine KD; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Wooters M; Harvard Medical School, Boston, Massachusetts, USA.
  • Wynn J; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, Massachusetts, USA.
  • Wardyn A; Billion to One, Inc., Menlo Park, California, USA.
  • Amendola L; School of Medicine, University of South Carolina, Columbia, South Carolina, USA.
  • Sepucha KR; Illumina, Inc., San Diego, California, USA.
  • Shannon KM; Massachusetts General Hospital, Boston, Massachusetts, USA.
J Genet Couns ; 32(5): 957-964, 2023 10.
Article em En | MEDLINE | ID: mdl-37069832
ABSTRACT
This study aimed to evaluate feasibility, acceptability, reliability, and validity of the existing four-item Shared Decision Making (SDM) Process Scale for use in evaluating genetic testing decisions. Patients from a large hereditary cancer genetics practice were invited to participate in a two-part survey after completing pre-test genetic counseling. The online survey included the SDM Process Scale and the SURE scale, a measure of decisional conflict. SDM Process scores were compared to SURE scores to test convergent validity, and respondents were sent a second survey 1 week later to assess retest reliability. The response rate was 65% (n = 259/398) and missing data was low (<1%). SDM scores ranged from zero to four with a mean of 2.3 (SD = 1.1). Retest reliability was good, with intraclass correlation of 0.84, 95% confidence interval (0.79, 0.88). No relationship was found between SDM Process scores and decisional conflict (p = 0.46), likely because 85% of participants reported no decisional conflict. The four-item SDM Process Scale demonstrated feasibility, acceptability, and retest reliability, but not convergent validity with decisional conflict. These findings provide initial evidence for use of this scale to measure patient perceptions of SDM in pre-test counseling for hereditary cancer genetic testing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tomada de Decisão Compartilhada / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tomada de Decisão Compartilhada / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article